The University of Chicago Header Logo

Connection

Tamara Vokes to Hypoparathyroidism

Back to Details
This is a "connection" page, showing publications Tamara Vokes has written about Hypoparathyroidism.
Tamara Vokes
Connection Strength
4.293
Hypoparathyroidism
  1. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019 11 01; 104(11):5136-5147.
    View in: PubMed
    Score: 0.616
  2. Quality of Life in Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018 12; 47(4):855-864.
    View in: PubMed
    Score: 0.572
  3. Quality of life in hypoparathyroidism. Bone. 2019 03; 120:542-547.
    View in: PubMed
    Score: 0.570
  4. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. J Clin Endocrinol Metab. 2018 02 01; 103(2):722-731.
    View in: PubMed
    Score: 0.545
  5. rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
    View in: PubMed
    Score: 0.229
  6. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):951-960.
    View in: PubMed
    Score: 0.223
  7. Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey. J Bone Miner Res. 2022 12; 37(12):2630-2641.
    View in: PubMed
    Score: 0.190
  8. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023 01; 38(1):14-25.
    View in: PubMed
    Score: 0.190
  9. Management of Hypoparathyroidism. J Bone Miner Res. 2022 12; 37(12):2663-2677.
    View in: PubMed
    Score: 0.189
  10. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 01 01; 107(1):e372-e385.
    View in: PubMed
    Score: 0.179
  11. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord. 2021 Nov 20; 21(1):232.
    View in: PubMed
    Score: 0.177
  12. Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-µg or 50-µg Daily Doses. Clin Ther. 2017 Oct; 39(10):2096-2102.
    View in: PubMed
    Score: 0.133
  13. Hypoparathyroidism. Nat Rev Dis Primers. 2017 08 31; 3:17055.
    View in: PubMed
    Score: 0.132
  14. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017 Jan; 55(1):273-282.
    View in: PubMed
    Score: 0.125
  15. Presentation of Hypoparathyroidism: Etiologies and Clinical Features. J Clin Endocrinol Metab. 2016 06; 101(6):2300-12.
    View in: PubMed
    Score: 0.119
  16. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):275-83.
    View in: PubMed
    Score: 0.101
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.